Picard Medical, Inc. commemorates its transition to the public markets by ringing the Opening Bell at the New York Stock Exchange.
The company continues to advance its Total Artificial Heart technology for patients with end-stage heart failure.
Picard Medical is the parent company of SynCardia Systems LLC, known for the world's first total artificial heart.
Transition to Public Markets
Picard Medical celebrates becoming a newly public company, enhancing its ability to advance its artificial heart platform.
Total Artificial Heart Technology
SynCardia's Total Artificial Heart is FDA and Health Canada approved, with over 2,100 implants globally, leading in artificial heart technology.
Next-Generation Technology
The company aims to create long-term value by developing the fully implantable Emperor system, the next-generation Total Artificial Heart.
- The ringing of the NYSE Opening Bell signifies Picard Medical's significant milestone in the healthcare industry.
- Becoming a public company enhances Picard's market presence and financial capabilities for further innovation and growth.
Picard Medical's transition to a public company marks a pivotal moment in advancing heart health technology and signifies a commitment to improving patient outcomes worldwide.